Sort   by:  
 Page size 
UnknownPhase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Not available
S-EPMC4509631 | biostudies-literature
UnknownEfficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Not available
S-EPMC8803998 | biostudies-literature
UnknownRuxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Not available
S-EPMC4223534 | biostudies-literature
UnknownEffect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC4979167 | biostudies-literature
UnknownGivinostat: an emerging treatment for polycythemia vera.
Not available
S-EPMC7534842 | biostudies-literature
UnknownNovel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Not available
S-EPMC5537055 | biostudies-literature
UnknownHow I manage anemia related to myelofibrosis and its treatment regimens.
Not available
S-EPMC9998582 | biostudies-literature
UnknownAdvanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Not available
S-EPMC3761194 | biostudies-literature
UnknownCharacteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Not available
S-EPMC5544569 | biostudies-literature
UnknownPrognosis of Primary Myelofibrosis in the Genomic Era.
Not available
S-EPMC4987499 | biostudies-literature
Sort   by:  
 Page size